TomoTherapy Advances in Mesothelioma Treatment TomoTherapy, a new advanced form of radiation therapy, was developed by the company named TomoTherapy Incorporated. The manufacturer announced recent findings at the European Society for Therapeutic Radiology and Oncology in Barcelona, Spain. The company conducted an overview of 80 studies that were done in order to research the effects of TomoTherapy on the treatment of several cancers such as head, neck, blood, breast, prostate, and lung cancers. This form of radiation therapy has been used in the treatment of several aggressive cancers, including a form of cancer caused by exposure to asbestos, known as mesothelioma. Studies were performed in order to compare the effects of RapidArc radiation treatment with TomoTherapy radiation. This research showed that TomoTherapy was far more efficient at the targeting of cancer without damaging the surrounding tissues and organs. A separate study researched the effects of TomoTherapy on mesothelioma, as well as other aggressive cancers. The study was conducted at the Greater Poland Cancer Center located in Poznan, Poland, and also at the San Raffaele Scientific Institute in Milan, Italy. Mesothelioma typically results in the development of aggressive tumors in various areas of the body such as the chest, abdomen, lungs, and in the mesothelium - or lining - of other various organs and bodily structures. In the study performed, two mesothelioma patient groups were formed and both were treated with TomoTherapy. One of the groups in question received the TomoTherapy SIB or simultaneous integrated boost while the other group did not receive the treatment. It was found that the patients who received the SIB treatment had a 72% increase in one-year survival while the group that did not only experienced an increase of 43%. It was also found that the treatment group experienced longer cases of relapse. Unfortunately, the prognosis of mesothelioma is rarely positive. It is often not diagnosed until the later stages of the cancer, when the cancer has already spread to other areas of the body from the mesothelium. Mesothelioma rarely exhibits symptoms until several decades, often 50 years, after the initial exposure to asbestos and, even when symptoms present, they are often not definitively indicative of cancer. TomoTherapy has shown promise in increasing the likelihood of a favorable prognosis.